Open AccessPhase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting 68Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer
Author(s) -
Minseok Suh,
Hyun Gee Ryoo,
Keon Wook Kang,
Jae Min Jeong,
Chang Wook Jeong,
Cheol Kwak,
Gi Jeong Cheon
Publication year - 2022
Publication title -
korean journal of radiology/korean journal of radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.08
H-Index - 57
eISSN - 2005-8330
pISSN - 1229-6929
DOI - 10.3348/kjr.2022.0176
Subject(s) - medicine , prostate cancer , nuclear medicine , glutamate carboxypeptidase ii , adverse effect , prostate , clinical trial , cancer , dosimetry , urology
68 Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane- N , N ', N ″-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I clinical trial of 68 Ga-NGUL was conducted to evaluate the safety and radiation dosimetry of 68 Ga-NGUL in healthy volunteers and the lesion detection rate of 68 Ga-NGUL in patients with prostate cancer.